Bioprocessing

Agreement enhances Lonza’s bioprocessing and QC solutions with validated four-day sterility testing.

Collaboration leverages AI-driven predictive modeling to cut AAV stable cell line development timelines by up to 70%, reducing cost and accelerating path to clinic.

Journey through the story of cell culture media in biopharmaceutical manufacturing - once considered mere cellular 'broth', now a critical component of modern medicine.

First commercial cell culture solution tailored for HEK293 cells in perfusion, enabling high-density growth, scalable viral vector production, and consistent quality for advanced therapies.

The collaboration highlights growing efforts to overcome manufacturing hurdles in gene therapy and bring treatments for debilitating neuromuscular junction diseases closer to patients.

The 128,000-sq-ft GMP cell and gene therapy facility in New Jersey, expands the CDMOs U.S. capabilities in plasmid, AAV, and LVV manufacturing.